Peter J. Weiden


University of Illinois at Chicago
Department of Psychiatry
Neuropsychiatric Institute
912 S. Wood Street, (M/C 913)
Chicago, IL 60612

Office Phone: (312) 996-9986
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Adriana Magana, 312-996-9986, This email address is being protected from spambots. You need JavaScript enabled to view it.


Weiden PJ, Havens LL: Psychotherapeutic management techniques in the treatment of outpatients with schizophrenia. Hospital and Community Psychiatry 45:549–55 (1994)

Weiden PJ, Rapkin B, Mott T, Zygmunt A, Goldman D, Frances A: Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophrenia Bulletin 20:297–310 (1994)

Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophrenia Bulletin 21: 419-429 (1995)

Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric services (Washington D.C.) 55:8 886-891 (2004)

Turkington D, Kingdon D, Weiden PJ: Cognitive behavioral therapy for schizophrenia. American Journal of Psychiatry 163: 365-373 (2006)

Weiden PJ, Buckley P: Reducing the burden of side effects during long-term antipsychotic therapy: The role of “switching” medications Journal of Clinical Psychiatry 68 [suppl 6]:14-23 (2007)

Weiden, PJ: Understanding and addressing adherence issues in schizophrenia: From theory to practice. Journal of Clinical Psychiatry; 68 (suppl 14) 14-19 (2007)

Weiden PJ, Newcomer J, Loebel A, Yang R, Lebovitz H: Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33: 958-994 (2008)

Weiden PJ: Antipsychotic-induced movement disorders – forgotten but not gone. Acta Psychiatrica Scandinavica 117:401-402 (2008) 

Weiden PJ, Preskorn S, Fahnstock P, Carpenter D, Ross R, Docherty J: Translating the Psychopharmacology of Antipsychotics to Individualized Treatment of Severe Mental Illness: A Roadmap (Special Issue, Journal of Clinical Psychiatry, 68 (Suppl 7): 1-44 (2007)

Peter J. Weiden, MD

Director of Psychotic Disorders Program

Peter J. Weiden, MD, is a Professor of Psychiatry and Director of the Psychotic Disorders Program at the Center for Cognitive Medicine at University of Illinois Medical Center (UIC) in Chicago, Illinois.

He received his undergraduate degree at Swarthmore College in Swarthmore, Pennsylvania, and his medical degree at SUNY Stony Brook. Dr. Weiden completed his psychiatric residency at Payne Whitney Clinic–New York Hospital in 1985 and a psychiatric epidemiology fellowship at Mailman School of Public Health at Columbia University in 1999.

Dr. Weiden has focused on improving clinical outcomes for patients with schizophrenia. In particular, his research career has focused on bridging psychopharmacology and public health issues in the treatment of schizophrenia. He has published extensively on the problem of medication nonadherence (noncompliance) in schizophrenia and has helped develop some of the current models and measures for nonadherence.

Dr. Weiden’s current research interests focus on pharmacologic and psychotherapeutic approaches to better address medication adherence problems for persons with schizophrenia. He is studying the effectiveness of early intervention using a combination of long-acting medication route and psychoeducation for “first-episode” schizophrenia patients. Dr. Weiden is currently testing an adherence intervention based on a CBT model to improve medication effectiveness for patients with “first-episode” schizophrenia, and is conducting an NIMH-funded clinical trial evaluating whether a CBT based psychotherapeutic intervention can reduce the adverse impact of medication nonadherence in young adults who have just begun maintenance medication therapy after an initial psychotic episode.

First-episode psychosis, Medication Adherence, Psychopharmacology, Cognitive Behavioral Therapy for Psychosis

American Psychiatric Association
Illinois Psychiatric Society
Scientific Review Group
Scientific Advisory Board, National Alliance of the Mentally Ill (NAMI)
Board of Directors, NAMI-Metro (New York City)
Member, International CBT for Psychosis Working Group
Member, Academy of Cognitive Therapy

NIMH funded study entitled: “Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention”